Enterprise Value
44.29M
Cash
6.38M
Avg Qtr Burn
-9.064M
Short % of Float
5.47%
Insider Ownership
14.30%
Institutional Own.
31.84%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OLPRUVA™ (ACER-001) Details Urea cycle disorder | Approved Quarterly sales | |
EDSIVO™ (celiprolol) Details Genetic disorder | Phase 3 Data readout | |
ACER-801 (osanetant) Details Menopause, Hot flashes | Failed Discontinued |